Shannon Strom

CONTACT

Lead Sponsor

Aerogen Pharma Limited

Age

0 - 0 years

Sex

ALL

Healthy Volunteers

No

•1. Inborn at the study site's hospital (i.e., not transferred from another hospital following delivery)
•2. Gestational age at birth of 26 through 33 weeks PMA
•3. Birth weight appropriate for gestational age (AGA, weight 3rd to 97th percentile on Fenton Growth Curve)
•4. Birth weight ≤ 2000 grams
•5. Post-natal age 1 to 24 hours at randomization
•6. On nCPAP or NIV for at least 30 minutes with RSS = 1.4 - 2.0 to maintain SpO2 90-95% at randomization. RSS is calculated as (nCPAP cm H2O) × (FiO2) or as (NIV mean airway pressure cm H2O) × (FiO2).
•7. FiO2 ≥ 0.24 at randomization
•8. nCPAP or mPaw ≥ 6 cm H2O at randomization
•9. Chest radiograph (CXR) or lung ultrasound compatible with RDS prior to randomization

•1. On SiPAP®, RAM® cannula, or high flow nasal cannula (HFNC) (\> 2 liters per minute \[LPM\]) at the time of randomization
•2. Prior instillation of surfactant
•3. Premature rupture of membranes (PROM) occurring \> 14 days before birth
•4. Significant congenital/chromosomal anomaly (e.g., Pierre Robin syndrome, clinically significant congenital heart disease, or trisomy)
•5. Pneumothorax
•6. Other etiologies of respiratory distress
•7. Enrollment in another interventional study with similar efficacy endpoints
•8. Apgar score at 5 min of 0-3
•9. Prior cardiopulmonary resuscitation (CPR) or epinephrine
•10. Base Deficit \> 15 mEq/L on most recent arterial blood gas (not capillary blood gas, venous blood gas, or cord gas) prior to randomization. Note that arterial blood gas is not required prior to randomization.
•11. Partial pressure of carbon dioxide (PaCO2) \> 65 mmHg on most recent arterial blood gas (not capillary blood gas, venous blood gas, or cord gas) prior to randomization.
•12. Triplet or higher order multiple birth

Related studies

NCT07261787 · Neonates and Preterm Infants, Infant Respiratory Distress Syndrome, and more

NCT07251790 · Respiratory Distress Syndrome, Newborn, Respiratory Distress Syndrome in Premature Infant

NCT04565665 · COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome, and more

NCT07504731 · Acute Respiratory Distress Syndrome (ARDS)

NCT06703073 · Acute Respiratory Distress Syndrome (ARDS), ARDS, and more

Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome